Eli Lilly stock jumped Wednesday on a solid beat-and-raise thanks to its GLP-1 drugs, treatments for diabetes and obesity. The post Eli Lilly's Diabetes And Obesity Drugs Blow Past Expectations; Shares Pop appeared first on Investor's Business Daily.